The conference call is slated for 8:00 a.m. Eastern Daylight Time on Wednesday, August 12. Investors and analysts may join via telephone or through a live webcast hosted on the company’s investor relations portal. Participants are advised to access the platform at least 15 minutes before the start time to complete registration and ensure software compatibility. A recording of the session will remain accessible on the company’s website for two weeks following the event.

Protalix continues to focus on its proprietary ProCellEx platform, which produces recombinant therapeutic proteins without exposure to mammalian cells. The company currently maintains partnerships with Pfizer for the commercialization of Elelyso and with Chiesi Farmaceutici for Elfabrio. Beyond these existing therapies, the leadership team is expected to discuss the status of its development pipeline, including PRX–115 for uncontrolled gout and the long-acting DNase I candidate, PRX–119.